JPH0121132B2 - - Google Patents
Info
- Publication number
- JPH0121132B2 JPH0121132B2 JP54173974A JP17397479A JPH0121132B2 JP H0121132 B2 JPH0121132 B2 JP H0121132B2 JP 54173974 A JP54173974 A JP 54173974A JP 17397479 A JP17397479 A JP 17397479A JP H0121132 B2 JPH0121132 B2 JP H0121132B2
- Authority
- JP
- Japan
- Prior art keywords
- glycerylphosphorylcholine
- rats
- antilipidemic
- administered
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000008777 Glycerylphosphorylcholine Substances 0.000 claims description 17
- 239000003524 antilipemic agent Substances 0.000 claims description 8
- 229960004956 glycerylphosphorylcholine Drugs 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- SUHOQUVVVLNYQR-MRVPVSSYSA-O glycerylphosphorylcholine Chemical compound C[N+](C)(C)CCO[P@](O)(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-O 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000006201 parenteral dosage form Substances 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 14
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 102000015779 HDL Lipoproteins Human genes 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 150000005830 nonesterified fatty acids Chemical class 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 230000004130 lipolysis Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- VAPZPBBPRKQWNR-AKGZTFGVSA-N OCC(O)CP(=O)=N[C@@H](CO)C(O)=O Chemical compound OCC(O)CP(=O)=N[C@@H](CO)C(O)=O VAPZPBBPRKQWNR-AKGZTFGVSA-N 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000002114 anti-triglyceridemic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- FRMZOWIQVCBEAC-UHFFFAOYSA-N glycerylphosphorylethanolamine Chemical compound OCCN(P(O)(O)=O)CC(O)CO FRMZOWIQVCBEAC-UHFFFAOYSA-N 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 231100000456 subacute toxicity Toxicity 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT25706/79A IT1123142B (it) | 1979-09-14 | 1979-09-14 | Uso di glicerilfosforil derivati nella terapia di dislipemie ed epatiti,e composizioni farmaceutiche relative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5643212A JPS5643212A (en) | 1981-04-21 |
| JPH0121132B2 true JPH0121132B2 (nl) | 1989-04-19 |
Family
ID=11217502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP17397479A Granted JPS5643212A (en) | 1979-09-14 | 1979-12-27 | Treating agent for lipemia* alcoholism* acute* subacute and chronic hepatitis* obesity and similar pathological symtoms |
Country Status (10)
| Country | Link |
|---|---|
| JP (1) | JPS5643212A (nl) |
| AU (1) | AU520245B2 (nl) |
| BE (1) | BE881071A (nl) |
| CH (1) | CH645543A5 (nl) |
| DE (1) | DE3000139C2 (nl) |
| FR (1) | FR2464715A1 (nl) |
| GB (1) | GB2057872B (nl) |
| IT (1) | IT1123142B (nl) |
| NL (1) | NL179873C (nl) |
| ZA (1) | ZA796882B (nl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1199972B (it) * | 1985-05-08 | 1989-01-05 | Lpb Ist Farm | Composizioni farmaceutiche per la terapia di sindromi cerebrali involutive e del decadimento mentale |
| JPH0751588B2 (ja) * | 1985-07-03 | 1995-06-05 | ハフスルント・ニコメド・フアルマ・アクチエンゲゼルシヤフト | グリセロ―３（２）―ホスホ―ｌ―セリン誘導体又はその塩及びこれを含有する薬学的調製物 |
| IT1213034B (it) * | 1986-02-12 | 1989-12-07 | Istituto Chemioterapico Di Lod | Composizioni farmaceutiche per la terapia di cerebropatie su base organica e funzionale. |
| IT1212137B (it) * | 1987-04-08 | 1989-11-08 | Rosanna Lodi | Composizioni farmaceutiche per il trattamento di sindromi psico-organiche cerebrali. |
| EP0329053A1 (en) * | 1988-02-15 | 1989-08-23 | MAGIS FARMACEUTICI S.p.A. | Choline esters of glycerophosphoric acids |
| EP0348859A1 (en) * | 1988-07-01 | 1990-01-03 | MAGIS FARMACEUTICI S.p.A. | 1,2-di-O-acyl glycero(DI)phosphate of L-carnitine and its derivatives, a process for their preparation and pharmaceutical formulations which contain them |
| IT1230140B (it) * | 1989-05-03 | 1991-10-14 | Fidia Spa | Derivati della serina, loro processo di preparazione e impiego in terapia umana |
| JP4891522B2 (ja) * | 2003-10-03 | 2012-03-07 | 株式会社ファンケル | 血清ｇｏｔ、ｇｐｔ改善剤 |
| CN102138892B (zh) * | 2010-02-03 | 2014-07-30 | 广州汉光医药进出口有限公司 | 甘磷酸胆碱注射制剂及其配制方法和检测方法 |
| JP2014051459A (ja) * | 2012-09-07 | 2014-03-20 | Nof Corp | 脂質代謝促進剤 |
| CN116966191A (zh) * | 2022-04-22 | 2023-10-31 | 深圳先进技术研究院 | 甘油磷酸胆碱在调控细胞nad+水平和分布中的应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54117034A (en) * | 1978-02-28 | 1979-09-11 | Nippon Shoji Kk | Treating agent for consciousness and perception motion disorder |
-
1979
- 1979-09-14 IT IT25706/79A patent/IT1123142B/it active
- 1979-12-12 GB GB7942835A patent/GB2057872B/en not_active Expired
- 1979-12-13 AU AU53792/79A patent/AU520245B2/en not_active Ceased
- 1979-12-19 ZA ZA00796882A patent/ZA796882B/xx unknown
- 1979-12-27 JP JP17397479A patent/JPS5643212A/ja active Granted
-
1980
- 1980-01-04 DE DE3000139A patent/DE3000139C2/de not_active Expired
- 1980-01-09 NL NLAANVRAGE8000140,A patent/NL179873C/nl not_active IP Right Cessation
- 1980-01-10 BE BE2/58326A patent/BE881071A/fr not_active IP Right Cessation
- 1980-01-17 FR FR8001004A patent/FR2464715A1/fr active Granted
- 1980-02-05 CH CH89980A patent/CH645543A5/it not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5643212A (en) | 1981-04-21 |
| AU5379279A (en) | 1981-04-02 |
| NL179873C (nl) | 1986-12-01 |
| ZA796882B (en) | 1980-11-26 |
| DE3000139A1 (de) | 1981-04-02 |
| NL8000140A (nl) | 1981-03-17 |
| IT7925706A0 (it) | 1979-09-14 |
| GB2057872B (en) | 1984-01-11 |
| AU520245B2 (en) | 1982-01-21 |
| GB2057872A (en) | 1981-04-08 |
| BE881071A (fr) | 1980-05-02 |
| CH645543A5 (it) | 1984-10-15 |
| FR2464715A1 (fr) | 1981-03-20 |
| NL179873B (nl) | 1986-07-01 |
| FR2464715B1 (nl) | 1983-07-22 |
| DE3000139C2 (de) | 1986-05-22 |
| IT1123142B (it) | 1986-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4507323A (en) | Treatment of psychosexual dysfunctions | |
| EP0306060B1 (en) | Pharmaceutical products providing enhanced analgesia | |
| JPS58154511A (ja) | 体重減少剤 | |
| KR20020027463A (ko) | 스핀고신-1-인산 수용체 아고니스트 또는스핀고신-1-인산을 유효 성분으로서 함유하는 선유화 억제제 | |
| US4804669A (en) | Treatment of pain with a piperidine | |
| EP0546796A1 (en) | Treatment of Atherosclerosis | |
| JPH0121132B2 (nl) | ||
| JP2002537258A5 (nl) | ||
| EP0171227B1 (en) | Use of propiophenone compound | |
| US5416105A (en) | Treating an arteriosclerosis with glimepiride | |
| US4362741A (en) | Therapeutic composition for preventing the aggregation of platelets | |
| US4088778A (en) | Method for the treatment of hypertension | |
| EP0303232B1 (en) | Use of benzylpyridine derivatives in the manufacture of a medicament for the treatment of dementia | |
| JPH01265027A (ja) | 肝疾患治療剤 | |
| JPS6245525A (ja) | 脂質低下剤 | |
| JP2627914B2 (ja) | プロスタグランジン類の選択的作用増強剤 | |
| CA3136230A1 (en) | Pharmaceutical combination of pimozide and methotrexate and use thereof | |
| US4505933A (en) | Fatty aldehydes in the treatment of Multiple Sclerosis | |
| EP2146714B1 (fr) | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson | |
| US3932652A (en) | Antidepressant compositions | |
| WO1990011080A1 (fr) | Medicament ameliorant les fonctions cerebrales | |
| JP7257091B2 (ja) | 認知症の治療及び予防薬 | |
| JPH0333715B2 (nl) | ||
| JP2009143929A (ja) | 睡眠障害の予防・治療剤 | |
| JPH02262519A (ja) | 糖尿病性神経障害治療剤 |